In module 2 of this case escalation series, Dr. Hurvitz presents the case of an obese 69-year-old woman with baseline prediabetes who has PIK3CA-mutated, HR+, HER2-negative metastatic breast cancer that has progressed on an aromatase inhibitor + CDK4/6 inhibitor.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
AMA PRA Category 1 Credit™Up to 0.25 creditsNursingUp to 0.25 credits
MOC types
No MOC
FDA REMS
No
Qualifies for MIPS
No
Pricing
100% of listed courses are free
189 of 189 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Clinical Informatics
- Communication & Shared Decision-Making
- Dermatology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General & Adult Psychiatry
- General Internal Medicine
- General Pediatrics
- Geriatric Medicine
- Gynecologic Oncology
- Health Equity & Inclusion
- Hematology
- Infectious Disease
- Medical Genetics & Genomics
- Medical Oncology
- Metabolic & Bariatric Surgery
- Nephrology
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Orthopaedic Surgery
- Pain Medicine
- Patient Education & Health Literacy
- Pediatric Gastroenterology
- Pediatric Neurology
- Physical Medicine & Rehabilitation
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Orthopedics
- Pain & Palliative
- Pediatrics
- Primary care
- Psychiatry
- Rehabilitation
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
- On-demand / recorded video
- includes Online course / module
- Credit · Up to 0.25 credits
- Commercial Support
-
ReleasedOct 22, 2025
-
Last day to claim creditOct 23, 2026 11 days left
-
Med Learning Group Balancing Benefits and Blood Sugar: A Team Approach to PI3K Pathway Inhibitors in HR+/HER2- Metastatic Breast Cancer Module 3
-
Med Learning Group Balancing Benefits and Blood Sugar: A Team Approach to PI3K Pathway Inhibitors in HR+/HER2- Metastatic Breast Cancer
-
Med Learning Group New Strategies for First-Line HER2-Positive Breast Cancer: Moving Current Therapies into Earlier Settings
-
PRIME Education, Inc. (PRIME®) Bridging Specialties to Manage Hyperglycemia in Breast Cancer Patients Treated With PI3K/AKT Pathway Inhibitors
-
Annenberg Center for Health Sciences at Eisenhower Pick the Best Path: Optimizing PIK3CA Mutation-Targeted HR+/HER2- PIK3CA-Mutated Therapy and Hyperglycemia Management
-
Efficient CME, CME Outfitters, LLC Individualizing the Journey Through Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Testing, Treatments, and Real Patient Experiences in PI3K-Pathway Altered Disease
